433 related articles for article (PubMed ID: 16212004)
61. Evaluation and management of obesity-related nonalcoholic fatty liver disease.
Nugent C; Younossi ZM
Nat Clin Pract Gastroenterol Hepatol; 2007 Aug; 4(8):432-41. PubMed ID: 17667992
[TBL] [Abstract][Full Text] [Related]
62. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
[TBL] [Abstract][Full Text] [Related]
63. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
[TBL] [Abstract][Full Text] [Related]
64. Review article: Drug therapy for non-alcoholic fatty liver disease.
Comar KM; Sterling RK
Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
[TBL] [Abstract][Full Text] [Related]
65. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
66. [Diagnosis and therapy in NASH].
Tokushige K
Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
[TBL] [Abstract][Full Text] [Related]
67. Non-alcoholic steatohepatitis in morbidly obese patients.
Tran A; Gual P
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):17-29. PubMed ID: 23347840
[TBL] [Abstract][Full Text] [Related]
68. [Alcoholic and non-alcoholic fatty liver hepatitis. When is abstaining from alcohol enough, when do steroids help?].
Berghaus TM; Beuers U
MMW Fortschr Med; 2001 Jul; 143(26-27):28-32. PubMed ID: 11481912
[TBL] [Abstract][Full Text] [Related]
69. Morphology of alcoholic liver disease.
Lefkowitch JH
Clin Liver Dis; 2005 Feb; 9(1):37-53. PubMed ID: 15763228
[TBL] [Abstract][Full Text] [Related]
70. Environmental and genetic determinants of fatty liver in humans.
Kantartzis K; Schick F; Häring HU; Stefan N
Dig Dis; 2010; 28(1):169-78. PubMed ID: 20460907
[TBL] [Abstract][Full Text] [Related]
71. Obesity and alcoholic liver disease.
Diehl AM
Alcohol; 2004 Aug; 34(1):81-7. PubMed ID: 15670669
[TBL] [Abstract][Full Text] [Related]
72. Nonalcoholic fatty liver disease: a review.
Poordad FF
Expert Opin Emerg Drugs; 2005 Aug; 10(3):661-70. PubMed ID: 16083334
[TBL] [Abstract][Full Text] [Related]
73. [Role of lipid peroxidation in non-alcoholic steatohepatitis].
Fraenkel E; Lazúrová I; Fehér J
Orv Hetil; 2004 Mar; 145(12):611-8. PubMed ID: 15119115
[TBL] [Abstract][Full Text] [Related]
74. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?
Pattullo V; Douglas MW; George J
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):265-77. PubMed ID: 21476921
[TBL] [Abstract][Full Text] [Related]
75. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis?
Leclercq IA
Clin Sci (Lond); 2004 Mar; 106(3):235-7. PubMed ID: 14604432
[TBL] [Abstract][Full Text] [Related]
76. [Pathology of alcoholic liver disease].
Hegedús G
Orv Hetil; 2000 Feb; 141(7):331-6. PubMed ID: 10703221
[TBL] [Abstract][Full Text] [Related]
77. [Obesity and steatohepatitis. Histologic aspects].
Pichardo-Bahena R; Paz-Gómez FJ; Estrada-Villaseñor EG
Gac Med Mex; 2004; 140 Suppl 2():S33-40. PubMed ID: 15641470
[TBL] [Abstract][Full Text] [Related]
78. [Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?].
Gallego-Durán R; Ampuero J; Funuyet J; Romero-Gómez M
Gastroenterol Hepatol; 2013 Nov; 36(9):587-96. PubMed ID: 24011648
[TBL] [Abstract][Full Text] [Related]
79. [Non-alcoholic fatty liver disease: age peculiarities, breakthrough in pathogenetic therapy].
Pal'tsev AI; Sharapov IV; Gorbunova EN; Khomchenko TN; Kurganova IV; Soldatova GS; Eremina AA; Nikolaev IuA
Eksp Klin Gastroenterol; 2009; (8):19-25. PubMed ID: 20469674
[TBL] [Abstract][Full Text] [Related]
80. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis.
Salomone F; Li Volti G; Rosso C; Grosso G; Bugianesi E
J Gastroenterol Hepatol; 2013 Jul; 28(7):1202-8. PubMed ID: 23425054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
